A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Anne-Cecile Ezanno; Brice Malgras; Olivier Aoun; Amaury Delarge; Alice Doreille; Marc Pocard

doi:10.1515/pp-2021-0138

A severe oxaliplatin immune-induced syndrome after oxaliplatin-based pressurized intraperitoneal aerosol chemotherapy (PIPAC)

Pleura Peritoneum. 2022 Jan 31;7(1):35-38. doi: 10.1515/pp-2021-0138. eCollection 2022 Mar 1.

Authors

Anne-Cecile Ezanno¹, Brice Malgras¹, Olivier Aoun², Amaury Delarge³, Alice Doreille⁴, Marc Pocard⁵

Affiliations

¹ Department of Gastrointestinal and Endocrine Surgery, Bégin Military Hospital, St Mandé, France.
² 46th Medical Unit, 5th Armed Forces Medical Center, Strasbourg, France.
³ Department of Acute Care Unit, Bégin Military Hospital, St Mandé, France.
⁴ Department of Nephrology, Tenon Hospital, Paris, France.
⁵ Department of Gastrointestinal and Cancerology, Pitié Salpetrière Hospital, Paris, France.

Abstract

Objectives: Oxaliplatin immune-induced syndrome (OIIS) was recently recognized as an uncommon complication of oxaliplatin therapy.

Methods: We report an exceptionally OIIS after pressurized intraperitoneal aerosol chemotherapy (PIPAC).

Results: Our patient developed a severe OIIS probably related to the intraperitoneal administration of oxaliplatin. Specific tests were performed and detected high-titer antibodies to oxaliplatin.

Conclusions: The OIIS is a rare. Physicians had to be aware of that clinical situation because it could be reversible, even in case of peritoneal advanced disease, and ICU treatment is justified.

Keywords: PIPAC; colorectal cancer; drug reaction; hypersensitivity reaction; oxaliplatin; oxaliplatin immune-induced syndrome (OIIS).